Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients can be classified into different categories with different therapeutic approaches and prognoses based on their age and clinical findings. Although most patients respond adequately to first-line treatments, a high unmet need exists for second-line agents that can be used in patients who do not respond to or cannot tolerate first-line therapy.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.